Company Overview: ONCOSEC

About the Company

ONCOSEC
Facebook Tweeter Linkedin

Established in 2011, OncoSec Medical Incorporated is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.

OncoSec’s investigational platform, ImmunoPulse®, is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of ImmunoPulse® with DNA-based IL-12 demonstrated a local immune response, and subsequently, a systemic effect. We are currently conducting pre-clinical and clinical studies targeting various cancers in collaboration with several prominent academic medical centers and companies.

To date, study results have laid the groundwork for OncoSec’s expansion into new DNA-encoded therapeutic candidates and tumor indications. Data also indicates this platform shows clinical activity as a monotherapy and promise as a combination approach.


Investor Toolkit

Company News

  • OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc.

    SAN DIEGO, June 12, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that they have engaged in a preclinical agreement through the OncoSec Technology Access Program (TAP) with Jounce Therapeutics,...

  • OncoSec to Present at LD Micro Invitational

    SAN DIEGO, June 2, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will be featured as a presenting company at the upcoming LD Micro Invitational to be held on June 6-7, 2017 at...

  • OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017

    SAN DIEGO, June 1, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced third quarter and year-to-date financial results ended April 30, 2017. “We have made significant progress this past quarter in...

  • OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017

    SAN DIEGO, May 11, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal third quarter 2017 financial results conference call on Thursday, June 1...

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address